Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06383338




Registration number
NCT06383338
Ethics application status
Date submitted
21/03/2024
Date registered
25/04/2024

Titles & IDs
Public title
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
Scientific title
A Prospective Feasibility Study Investigating PhEnoconversion of CYP3A4, CYP2C19 and CYP2D6 Genotype in Paediatric and Adolescent and Young Adult patientS With an acUte diagnosiS of Hodgkin or Non-Hodgkin Lymphoma.
Secondary ID [1] 0 0
PEGASUS
Universal Trial Number (UTN)
Trial acronym
PEGASUS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hodgkin Lymphoma 0 0
Non Hodgkin Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Omeprazole
Treatment: Drugs - Dextromethorphan

Treatment: Drugs: Omeprazole
Sub-therapeutic probe drug administration to measure phenoconversion.

Treatment: Drugs: Dextromethorphan
Sub-therapeutic probe drug administration to measure phenoconversion.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of patients who consent to study and complete baseline and at least two longitudinal timepoints with successful measurement of probe drug MR (Metabolic ratio)
Timepoint [1] 0 0
12 months, 24 Months
Secondary outcome [1] 0 0
Percentage of participants completing all required longitudinal blood sampling
Timepoint [1] 0 0
Baseline through to 24 Months
Secondary outcome [2] 0 0
Proportion of participants with successful detection of probe drug overall and at each sampling timepoint
Timepoint [2] 0 0
Baseline through to 24 Months
Secondary outcome [3] 0 0
Proportion of participants where phenotype can be classified according to MR overall at each sampling timepoint
Timepoint [3] 0 0
Baseline through to 24 Months
Secondary outcome [4] 0 0
The level of acceptability of participation in pharmacogenomic & phenoconversion testing using the PEGASUS specific survey tool (based on the Theoretical Framework of Acceptability [TFA])
Timepoint [4] 0 0
Baseline through to 24 Months
Secondary outcome [5] 0 0
Percentage of participants experiencing an adverse event (AE) during probe drug administration
Timepoint [5] 0 0
Baseline through to 24 Months
Secondary outcome [6] 0 0
Incidence of genotype and phenotype mismatch, overall and across longitudinal timepoints
Timepoint [6] 0 0
Baseline through to 24 Months
Secondary outcome [7] 0 0
Proportion of participants with disease staging and biomarkers of extent of disease
Timepoint [7] 0 0
Baseline through to 24 Months
Secondary outcome [8] 0 0
Proportion of participants with a systemic inflammatory state
Timepoint [8] 0 0
Baseline through to 24 Months
Secondary outcome [9] 0 0
Proportion of participants taking medications involving the CYP P450 pathway
Timepoint [9] 0 0
Baseline through to 24 Months
Secondary outcome [10] 0 0
Participant demographic information
Timepoint [10] 0 0
Baseline
Secondary outcome [11] 0 0
Proportion of participants with other environmental factors
Timepoint [11] 0 0
Baseline through to 24 Months
Secondary outcome [12] 0 0
Longitudinal inflammatory profile of participants with Hodgkin or non-Hodgkin Lymphoma as measured by a panel including serum levels of procalcitonin, c-reactive protein and cytokine analysis.
Timepoint [12] 0 0
Baseline through to 24 Months

Eligibility
Key inclusion criteria
* Age 6-25 years of age.
* New diagnosis of Hodgkin Lymphoma or Non-Hodgkin Lymphoma.
* Able to swallow and absorb oral or nasogastric tube (NGT) administration of probe drugs.
* Able to provide written informed consent.
Minimum age
6 Years
Maximum age
25 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Failure to comply with inclusion criteria.
* Has a known previous allergy to any of the probe medications (i.e., omeprazole or dextromethorphan).
* Common Terminology Criteria for Adverse Events (CTCAE) Grade IV end organ dysfunction (i.e., hepatic, renal, gastrointestinal).
* Had previous oncological treatment (not first cancer diagnosis).
* Is a clinically unstable patient requiring intensive care admission in high-risk circumstances will not be considered eligible for consent.
* Any patient requiring urgent initiation of anti-cancer treatment outside hours where a member of the study staff is unable to approach the parent/guardian or participant for consent prior to commencing anti-cancer therapy will be ineligible for consent.
* Unable to provide written informed consent.

Study design
Purpose of the study
Other
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
1/03/2025
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/03/2026
Actual
Sample size
Target
10
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment postcode(s) [1] 0 0
3000 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Murdoch Childrens Research Institute
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Rachel Conyers, MBBS (Hons)
Address 0 0
Murdoch Children's Research Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Rachel Conyers, MBBS (Hons)
Address 0 0
Country 0 0
Phone 0 0
+61393455522
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06383338